Engrail Therapeutics is focused on developing precision-targeted therapeutics aimed at addressing significant unmet needs in neuropsychiatric and neurodevelopmental disorders. The company employs advanced methodologies in precision chemistry and pharmacology to create transformative medicines that enhance the lives of patients who have been underserved by existing treatments. Their innovative pipeline includes therapies that modulate GABA and dopamine neurotransmission, which are critical in managing conditions such as anxiety, depression, and other mood disorders. By leveraging their expertise in neurocircuitry and receptor pharmacology, Engrail aims to optimize drug profiles to maximize clinical benefits while minimizing side effects.

One of the key technologies utilized by Engrail Therapeutics is GABA modulation, specifically through the development of selective GABA A positive allosteric modulators (PAMs) that target specific receptor subunits to enhance therapeutic efficacy while reducing undesirable side effects associated with traditional benzodiazepines. Additionally, the company is advancing dopamine modulation therapies, particularly focusing on addressing anhedonia in depression through selective D2/D3 receptor antagonism. Engrail is also exploring copper transport mechanisms, with a unique approach to treat Menkes disease by developing a copper ionophore that facilitates proper copper distribution in the brain. This multifaceted approach underscores Engrail's commitment to precision neuroscience and its potential to deliver impactful treatments for complex neurological conditions.

United States

We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Engrail Therapeutics

Company Details